Dexmedetomine vs Dexamethasone in TAB Block for Abdominal Surgries

Ain Shams University

Status and phase: Active, not recruiting; Phase 4

Conditions: Anesthesia

Treatments: Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT05323565

FMASU M D 184/2020

Details and patient eligibility

About

Randomized controlled clinical Trial to compare the efficacy and duration of postoperative analgesia achieved after adding dexmedetomidine or dexamethasone to bupivacaine in TAP block for lower open abdominal surgeries.

Full description

A Comparative study between the use of dexmedetomidine versus dexamethasone as adjuvant to bupivacaine in ultrasound-guided transversus abdominis plane block for post-operative pain relief in patients undergoing lower open abdominal surgeries

Enrollment: 45 patients

Sex: All

Ages: 20 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Adult patients, Age 20-60 years. Elective operation under general anesthesia. Physical Status: ASA I and II Patients. Body mass index 25-35 kg/m2.

Exclusion criteria

• Infection at site of injection.
• Patient refusal.
• Psychiatric or physical illness that lead to inability to cooperate, speak or read.
• Abdominal operations under spinal anesthesia.
• History or evidence of coagulopathy.
• Known allergies to drugs used .
• Preexisting neurological disorders.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

45 participants in 3 patient groups

Group A (n=15): (Dexamethasone group)

Active Comparator group

Description:

Patients will receive 20 ml 0.25% bupivacaine plus 4 mg dexamethasone on each side TAB bock.

Treatment:

Drug: Dexmedetomidine

Group B (n=15): (Dexmedetomidine group)

Active Comparator group

Description:

Patients will receive 20 ml 0.25% bupivacaine plus 0.5 mcg/kg of dexmedetomidine on each side TAB block.

Treatment:

Drug: Dexmedetomidine

Group C (n=15): (control group)

Sham Comparator group

Description:

Patients will receive 20 ml 0.25% bupivacaine on each side TAB block.

Treatment:

Drug: Dexmedetomidine